Compass Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -368 | -370 | -367 | |
EBITDA | -17,949 | -15,346 | -14,240 | -19,514 |
EBIT | -18,317 | -15,716 | -14,259 | -19,881 |
Net Income | -18,317 | -15,716 | -14,259 | -19,881 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -17,351 | -13,254 | -10,856 | -11,832 |
Cash | 55,168 | 30,643 | 46,212 | 22,856 |
Basic Shares | 186,400 | 184,844 | 138,282 | 138,282 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $850 | $0 | $0 |
Gross Profit | -1,472 | 850 | -1,890 | -1,904 |
EBITDA | -65,017 | -47,622 | -40,604 | -34,961 |
EBIT | -66,489 | -49,375 | -42,494 | -36,865 |
Net Income | -66,489 | -49,375 | -42,494 | -39,225 |
Net Change In Cash | 0 | 850 | 0 | 0 |
Cost of Revenue | -109,568 | |||
Free Cash Flow | -49,168 | -44,899 | -40,648 | -34,337 |
Cash | 30,643 | 43,483 | 24,228 | 34,946 |
Basic Shares | 157,695 | 137,108 | 127,027 | 105,186 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.10 |
2025-12-31 | -$0.09 |
2025-09-30 | -$0.08 |
2025-06-30 | -$0.14 |